BioAtla, Inc. Financials

BCAB

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 7 available years

Income Statement	TTM	DEC 2025	DEC 2024	DEC 2023	DEC 2022	DEC 2021 4:1 split
Revenues
Revenue	$0	–	–	–	–	$0
General & Administrative	$26	$18	$22	$26	$29	$38
Research & Development	$101	$44	$63	$104	$79	$58
Total Operating Expenses	$127	$61	$85	$130	$108	$97
Operating Income	-$127	-$59	-$74	-$130	-$108	-$96
Non-Operating
Net Interest Expense	$5	$1	$3	$6	$2	$0
Other Non-Operating Income (Expense)	$5	-$0	$4	$6	$2	$1
Income Tax Expense	–	$0	$0	$0	$0	$0
Minority Interest	–	–	–	–	–	$0
Net Income
Net Income	-$122	-$60	-$70	-$123	-$106	-$95
Per Share Data
Revenue Per Share	$0.00	–	–	–	–	$0.43
EPS (Basic)	-$136.00	-$50.50	-$72.00	-$129.00	-$137.00	-$138.00
EPS (Diluted)	-$136.00	-$50.50	-$72.00	-$129.00	-$137.00	-$138.00
Weighted Avg Shares (Basic)	47.8M	58.8M	48.6M	47.8M	38.9M	34.6M
Weighted Avg Shares (Diluted)	47.8M	58.8M	48.6M	47.8M	38.9M	34.6M
Shares Outstanding	956,682.44	1.2M	971,467.28	955,551.36	778,545.36	691,224.9

BioAtla (BCAB) financials: revenue, profit and margins

BioAtla (BCAB) generated about n/a in revenue and -$31 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is BioAtla profitable?+

BioAtla reported about -$31 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

More on BCAB: Overview · Quality scorecard · DCF valuation · Dividend safety

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 13 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with BCAB

CompareIntrinsic value

ZIVOZivo Bioscience Inc.

$8.00+10.34%0

WINTWindtree Therapeutics Inc.

$0.00+0.00%10

ATYRAtyr Pharma Inc.

$6.18-6.79%10

VIVSVivoSim Labs, Inc.

$0.15+8.71%10

PALIPalisade Bio Inc.

$1.25+1.63%20

AIMAIM ImmunoTech Inc.

$0.16+0.63%15

CRDFCardiff Oncology Inc.

$0.87+1.03%36

INMBInmune Bio Inc.

$1.33+0.76%10

Spot a number that looks wrong? Check it in BCAB's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing BCAB

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.